Tom van Meerten

Tom van Meerten is Professor of Onco-Immunology at the University Medical Center Groningen. His research focuses on developing immunotherapies for hematological cancers, particularly CAR T-cell treatments for lymphomas.

Van Meerten leads clinical trials investigating treatments like brexucabtagene autoleucel for mantle cell lymphoma and explores PET imaging biomarkers for immunotherapy. His team recently secured €16.5 million in funding for CAR T-cell research in bone marrow cancer.